Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Patricia Glomb"'
Autor:
Patrick Schöffski, Holger Fritsch, Patricia Glomb, Ahmad Awada, Pascal Wolter, Gerd Munzert, Herlinde Dumez, S. Bartholomeus, M. Taton, Thierry Gil
Publikováno v:
European Journal of Cancer. 48:179-186
Background Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of vola
Autor:
Patricia Glomb, Arne Ring
Publikováno v:
Journal of biopharmaceutical statistics. 22(2)
In clinical development, thorough QT interval/corrected QT interval (QT/QTc) studies are performed to demonstrate that new investigational drugs do not change cardiac repolarization. In addition to the analysis recommended by ICH E14, exposure-respon
Autor:
Korinna Pilz, Tommaso De Pas, L. Clementi, Filippo de Braud, Gianluca Spitaleri, Stefano Cascinu, Dan Liu, Patricia Glomb
Publikováno v:
Journal of Clinical Oncology. 31:2556-2556
2556 Background: Volasertib (V) is a potent and selective cell cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases. Nintedanib (N) is a triple angiokinase inhibitor of VEGF, PDGF, and FGF receptors. Both ha
Autor:
Patricia Glomb, Patrick Schöffski, H. Fritsch, Herlinde Dumez, J. Selleslach, Gerd Munzert, Ahmad Awada, Thierry Gil, M. Taton, S. Bartholomeus
Publikováno v:
Journal of Clinical Oncology. 28:3061-3061
3061 Background: BI 6727 is a highly potent and selective inhibitor of the serine-threonine Polo-like kinase 1 (Plk1), a key regulator of cell cycle progression. BI 6727 is a second generation dihy...
Autor:
Glomb, Patricia1 (AUTHOR) patricia.glomb@boehringer-ingelheim.com, Ring, Arne1 (AUTHOR)
Publikováno v:
Journal of Biopharmaceutical Statistics. Mar/Apr2012, Vol. 22 Issue 2, p387-400. 14p.